Gossamer Bio, Inc. $GOSS

What the company doesAI summary of filing

Gossamer Bio is a clinical-stage biopharmaceutical company developing seralutinib, an inhaled kinase inhibitor targeting pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is not revenue-generating and has completed Phase 3 testing of seralutinib, which showed a placebo-adjusted improvement of 13.3 meters in six-minute walk distance at week 24 but did not meet its prespecified statistical threshold. In May 2024, Gossamer entered into a collaboration agreement with Chiesi under which it received $160 million upfront and is eligible for up to $326 million in regulatory and sales milestones, while Chiesi will lead commercialization outside the United States and Gossamer will co-lead commercialization in the US. The company also holds an option agreement for RT234, an inhaled on-demand PDE5 inhibitor for PAH and PH-ILD. [10-K 2026-03-17]

Segments: Seralutinib (inhaled PDGFR/CSF1R/c-KIT inhibitor for PAH and PH-ILD), RT234 (inhaled on-demand PDE5 inhibitor for PAH and PH-ILD)